Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued li…

Results of Operations and Financial Condition. On August 14, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2026 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under

Other Events. As previously disclosed by Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), on a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on July 16, 2026 (the “Prior Form 8-K”), in connection with the Company’s acquisition of Kira Pharmaceuticals (“Kira”), a former Cayman Islands exempted company, pursuant to that certain Agreement and Plan of Merger, dated July 16, 2026 (the “Merger Agreement”), by and among the…

by reference. Pursuant to the terms of the Merger Agreement, each option to purchase Kira ordinary shares was assumed by the Company and was converted into options (the “Options”) to purchase an aggregate of 392,791 shares of Common Stock and an aggregate of 351,201 shares of Preferred Stock. In addition, pursuant to the Merger Agreement, a total of 254,462 shares of Preferred Stock were issued to the holders of Company SAFEs (as defined in the Merger Agreement). Shares of Common Stock, optio…

of this Current Report on Form 8-K, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act. 7 Forward-Looking Statements Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptio…

Director — Vishal Kapoor and Scott Brun, M.D.: The resignations are part of a merger agreement and do not indicate any disagreement with the company.

The PIPE Securities were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the Investors represented that it was an “accredited investor,” as defined in Regulation D, and is acquiring the PIPE Securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The PIPE Securities have not been registered un…

Regulation FD Disclosure. On July 16, 2026, Jasper Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has completed the acquisition of Kira Pharmaceuticals, a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction and entered into a securities purchase agreement for a private placement financing for gross proceeds of $132 million. A copy of the press release is furni…

Completion of Acquisition or Disposition of Assets. On July 16, 2026, the Company completed its acquisition of Kira. The information contained in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550…

Director — Christian Nolet: Mr. Nolet resigned from the Board and its committees.

Results of Operations and Financial Condition. On May 14, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under

Results of Operations and Financial Condition. On March 30, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter and year ended December 31, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under

CEO and President — Ron Martell: Mr. Ron Martell ceased serving as the Company’s Chief Executive Officer and President, with Mr. Jeet Mahal appointed to replace him.

Results of Operations and Financial Condition. On November 10, 2025, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under

Other Events. On September 18, 2025, the Company provided the following corporate update on the ongoing investigation into the confounded efficacy results reported in July 2025 from the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts of the BEACON study in Chronic Spontaneous Urticaria (“CSU”): Based on the work conducted to date, the Company believes the anomalous efficacy results in these two cohorts do not appear to be related to drug substance (“DS”) or drug product (“DP”) manufactu…

Entry into a Material Definitive Agreement. On September 18, 2025, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC as the representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) an aggregate of 11,670,707 shares of the Company’s voting common stock (“Common Stock”) and accompanying warrants (the “Common Warrants…

Results of Operations and Financial Condition. On August 13, 2025, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under

Chief Medical Officer — Dr. Edwin Tucker, M.D.: Dr. Edwin Tucker will cease serving as the Company’s Chief Medical Officer due to corporate reorganization.

Other Events. On July 9, 2025, the Company issued a press release announcing a corporate reorganization and other cost cutting measures to extend its cash runway. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Forward-Looking Statements Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Privat…

Costs Associated with Exit or Disposal Activities. On July 8, 2025, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) approved a corporate reorganization to extend its cash runway, which includes a plan to reduce the Company’s workforce by approximately 50%. In connection with this corporate reorganization, the Company has refined its operating plan to focus on its briquilimab clinical development programs in chronic urticaria and is halting other clinical and…

Results of Operations and Financial Condition. On May 12, 2025, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under

or 7.01 of Form 8-K or to provide disclosure pursuant to

Results of Operations and Financial Condition. On February 27, 2025, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2024 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being fu…

Results of Operations and Financial Condition. On November 7, 2024, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2024 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under